Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:protocol:olmesartan:kidney_disease [05.09.2019]
sallieq [Elevated kidney values tend to be temporary]
home:protocol:olmesartan:kidney_disease [08.13.2019] (current)
sallieq [Benefits of olmesartan for patients with kidney disease]
Line 7: Line 7:
  
  
-===== Subclinical kidney infection ===== 
  
-Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:​pathogenesis:​th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:​pathogenesis::​microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test. 
- 
-Once patients activate the [[home:​pathogenesis:​innate_immunity|innate immune system]] with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests. 
  
  
Line 47: Line 43:
  
 "​Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function" ​ (({{pubmed>​long:​24062331}})) "​Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function" ​ (({{pubmed>​long:​24062331}}))
-===== Benefits ​of olmesartan ​for patients with kidney disease =====+ 
 +===== Subclinical kidney infection ===== 
 + 
 +Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:​pathogenesis:​th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:​pathogenesis::​microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test. 
 + 
 +Once patients activate the [[home:​pathogenesis:​innate_immunity|innate immune system]] with olmesartan ​and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests. 
 +===== Olmesartan benefits ​patients with kidney disease =====
  
 According to a 2008 commentary appearing in //Nature//: According to a 2008 commentary appearing in //Nature//:
Line 89: Line 91:
  
 ==== Animal studies ==== ==== Animal studies ====
 +
 +[[http://​hdl.handle.net/​1807/​96258|.Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.]]
  
 Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed>​long:​16985512}})) Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed>​long:​16985512}}))
home/protocol/olmesartan/kidney_disease.1557442536.txt.gz · Last modified: 05.09.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.